Vancomycin costs far more than you’d expect for a decades-old antibiotic with no patent protection. A standard 10-day course of oral vancomycin capsules can run $1,000 to $1,800 or more without insurance, and even with coverage, most patients face significant out-of-pocket costs. The reasons come down to a combination of complex manufacturing, limited competition among generic makers, ongoing supply shortages, and insurance plans that don’t do patients many favors.
A Complicated Drug to Manufacture
Unlike most antibiotics, vancomycin can’t be synthesized through straightforward chemistry. It’s produced through fermentation, meaning a specific soil bacterium (Amycolatopsis orientalis) grows in carefully controlled conditions and produces the drug as a natural byproduct. The process requires precise management of pH, temperature, oxygen levels, and agitation speed. Even small deviations can reduce the yield or compromise quality.
After fermentation, the raw product must go through extensive purification to isolate the active compound from everything else the bacteria produced. This multi-step process is more expensive and less predictable than manufacturing a simple chemical drug like amoxicillin. The oral capsule form adds another layer: the intravenous solution and the oral capsule are different products with separate regulatory approvals, separate manufacturing lines, and separate supply chains. All of this keeps production costs elevated even before the drug reaches a distributor.
Too Few Generic Competitors
Vancomycin lost patent protection years ago, and generic versions exist. But the generic market hasn’t driven prices down the way it does for most older drugs. The oral capsule market, which exceeded $100 million in 2015, has been dominated by a small handful of manufacturers. One of the original generic companies alone captured roughly 57% of the market, with the newest entrant holding only about 15%.
With so few players, there’s little incentive for aggressive price competition. New manufacturers have been slow to file for approval, possibly because the existing companies already control comfortable market shares and the fermentation-based manufacturing process creates a higher barrier to entry than a simple pill. The result is a generic market that behaves more like a soft monopoly than a competitive one.
Persistent Supply Shortages
Vancomycin, particularly the injectable form used in hospitals, has been in a state of rolling shortage for years. As of early 2025, multiple manufacturers have key products on back order with no firm release dates. Fresenius Kabi estimates its 1-gram vials won’t be available until spring 2026. Hikma cannot even estimate when several of its vial sizes or premixed bags will return. Sagent has most of its product line on back order through mid-2025 at the earliest, and Pfizer is releasing 1-gram vials in limited weekly batches.
These shortages reflect the fragility of fermentation-based supply chains. When one manufacturer has a production problem, the remaining companies can’t easily ramp up to fill the gap. Hospitals and pharmacies compete for limited stock, and that scarcity puts upward pressure on prices across the board. Premixed bags, which are the most convenient hospital formulation, are especially hard to find, with several suppliers listing them on indefinite back order.
Oral vs. IV: A Price Gap That Surprises People
One of the most confusing things about vancomycin pricing is the enormous difference between the oral and intravenous forms. The IV solution is relatively affordable, often costing hospitals just a few dollars per dose. The oral capsules, used primarily to treat C. difficile gut infections, can cost 100 times more per course of treatment.
This gap exists partly because the two forms serve different markets with different competitive dynamics. IV vancomycin has more manufacturers and higher volume, which keeps prices lower. Oral vancomycin capsules have fewer makers and a smaller but growing patient population, giving manufacturers more pricing power. Some patients and doctors have historically tried to bridge this gap by having patients drink the IV solution instead of taking capsules (since vancomycin works locally in the gut for C. difficile), but this workaround isn’t always available or practical.
Insurance Coverage That Falls Short
Even patients with insurance often face steep bills. A study of Medicare Part D plans found that while oral vancomycin technically appeared on 100% of plan formularies, it was “broadly accessible,” meaning on a low cost-sharing tier without restrictions, for only 14.4% of enrollees. That means the vast majority of Medicare beneficiaries with drug coverage still face prior authorization requirements, step therapy rules, or placement on a high-cost specialty tier that comes with significant copays or coinsurance.
For a drug that clinical guidelines recommend as a front-line treatment for C. difficile infections, this level of restriction is notable. The newer alternative, fidaxomicin, has an even higher sticker price and was broadly accessible to just 1.1% of Medicare enrollees. So patients needing treatment for C. difficile often face high costs regardless of which recommended drug they’re prescribed.
The C. Difficile Factor
Demand for oral vancomycin is closely tied to C. difficile infections, which cause roughly half a million illnesses per year in the United States. Clinical guidelines from the Infectious Diseases Society of America list vancomycin as an acceptable first-line treatment, and it remains the go-to option in many hospitals because the preferred alternative, fidaxomicin, costs even more upfront.
The math gets more complicated when you factor in recurrence. C. difficile comes back within 28 days in about 22.6% of patients treated with vancomycin, compared to 11.7% with fidaxomicin. For patients who’ve already had one episode, the recurrence gap widens: 35.5% with vancomycin versus 19.7% with fidaxomicin. Each recurrence means another course of treatment, more hospital visits, and more cost. Budget analyses have found that despite fidaxomicin’s higher price tag, hospitals can actually save $1,100 to $1,150 per year by using it instead of vancomycin for a portion of patients, simply because fewer patients bounce back with repeat infections.
This creates an odd dynamic where vancomycin is both the “cheaper” option and still expensive enough to cause real financial pain for patients. It occupies an uncomfortable middle ground: too costly for many patients to afford easily, but not expensive enough relative to alternatives for insurers to feel urgency about improving coverage.
Why Prices Haven’t Come Down
The short answer is that none of the forces that normally push drug prices lower are working effectively here. Patent expiration didn’t spark a flood of generic competitors. The manufacturing process is complex enough to discourage new entrants. Supply shortages keep existing inventory scarce. Insurance formularies treat the drug as a higher-tier product despite its front-line clinical role. And demand keeps growing as C. difficile infections remain common, particularly among older adults and people who’ve recently taken other antibiotics.
For patients facing a vancomycin prescription, the practical reality is that costs vary widely depending on the formulation (oral capsules vs. IV), the pharmacy, and insurance coverage. Manufacturer discount programs and pharmacy discount cards can sometimes reduce out-of-pocket costs for the oral form, but the underlying price structure is unlikely to change without either new generic competitors entering the market or policy changes that address how insurers tier essential antibiotics.